Listing of Claims:

1. (Currently amended) A compound ~~Compounds~~ of ~~the~~ formula I



I

in which

W ~~denotes~~ is CH or N,

R^1, R^2, R^3, independently of one another, ~~denote~~ are H, R, A, aryl, heteroaryl, Hal, $-(CY_2)_n-SA$, $-(CY_2)_n-SCF_3$, $-(CY_2)_n-SCN$, $-(CY_2)_n-CF_3$, $-(CY_2)_n-OCF_3$, cycloalkyl, $-SCH_3$, -SCN, $-CF_3$, $-OCF_3$, -OA, $-(CY_2)_n-OH$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$, $-(CY_2)_n-Hal$, $-(CY_2)_n-NR_2$, $(CY_2)_n-OA$, $(CY_2)_n-OCOA$, $-SCF_3$, $(CY_2)_n-CONR_2$, $-(CY_2)_n-NHCOA$, $-(CY_2)_n-NHSO_2A$, SF_5, $Si(CH_3)_3$, $CO-(CY_2)_n-CH_3$, $-(CY_2)_n$-N-pyrrolidone, $CH(CH_2)_nNRCOOR$, CHNRCOOR, NCO, $CH(CH_2)_nCOOR$, NCOOR, $CH(CH_2)_nOH$, $N(CH_2)_nOH$, $CHNH_2$, $CH(CH_2)_nNR_2$, $CH(CH_2)_nNR_2$, C(OH)R, CHNCOR, $CH(CH_2)_n$-aryl, $CH(CH_2)_n$--heteroaryl, $CH(CH_2)_nR^1$, $N(CH_2)_nCOOR$, $CH(CH_2)_nX(CH_2)_n$-aryl, $CH(CH_2)_nX(CH_2)_n$-heteroaryl, $N(CH_2)_nCONR_2$, $XCONR(CH_2)_nNR_2$, $N[(CH_2)_nXCOOR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_nX$-aryl, $N[(CH_2)_nXR]SO_2(CH_2)_n$-aryl, $N[(CH_2)_nNRCOOR]CO(CH_2)_n$-aryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-aryl, $N[(CH_2)_nNR_2]CO(CH_2)_nNR$-aryl, $N[(CH_2)_nNR_2]SO_2(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nXR]CO(CH_2)_nX$-heteroaryl,

$N[(CH_2)_nXR]SO_2(CH_2)_n$-heteroaryl, $N[(CH_2)_nNRCOOR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_nNR$-heteroaryl, $N[(CH_2)_nNR_2]SO_2(CH_2)_n$-heteroaryl, $O(CH_2)_nNR_2$, $X(CH_2)_nNR_2$, $NCO(CH_2)_nNR_2$, ~~or~~ R^1 and R^2 together ~~also~~ are ~~denote~~ -N-$C(CF_3)$=N-, -N-CR=N-, or -N-N=N-,

Y ~~denotes~~ is H, ~~A,~~ or Hal

A ~~denotes~~ is alkyl or cycloalkyl, in which one or more H atoms optionally are substituted ~~may be replaced~~ by Hal,

Hal ~~denotes~~ is F, Cl, Br or I,

R ~~denotes~~ is H or A, in the case of geminal radicals R together ~~also~~ is $-(CH_2)_5$-, $-(CH_2)_4$-, $-(CH_2)_2$-X-$(CH_2)_2$ or $-(CH_2)_2$-Z-$(CH_2)_n$,

R^4, R^5, independently of one another, ~~denote~~ are H or an unsubstituted or mono- or ~~poly~~ poly-substituted -OR-, NO_2-, Hal-, CF_3-, OCF_3-, CN-, NR_2-, ~~or~~ SR-, aryl-, ~~or~~ heteroaryl-substituted N-pyrrolidone ~~radical~~, -X-$(CH_2)_2OR$, -X-$CO(CH_2)_nCH_3$, -X-$(CH_2)_2NR_2$, R^1, S-aryl, O-aryl, $CH_2Si(CH_3)_3$, or together ~~denote~~ are -$X(CR_2)_2$-, -X-$(CR_2)_3$-, -X-$(CHCH_2OR)(CH_2)_2$-, -X-$(CHCH_2NR_2)(CH_2)_2$-, -$X(CH_2)_2NR_2$, -$(CR_2)_3$ -, -$(CR_2)_4$-, -CR=CR-CR=CR-, -XCHQ$(CR_2)_2$-, -XCHQCR_2-, R-N-(C=X)-N-R, or -$XC[(CH_2)nOR]_2CH_2CH_2$-,

X ~~denotes~~ is O, S or NR

Q ~~denotes~~ is CH_2Hal, CHO, COR^a, CH_2R^a, CH_2OCOR^a, CH_2NCOR^1, $CH_2N(R^1)_2$, CH_2OR^1, $CH_2OCON(R^1)_2$, CH_2OCOOR^1, $CH_2NHCON(R^1)_2$, or $CH_2NHCOOR^1$,

R^a ~~denotes~~ is


,


,


,


,


,


,


,


,


,


,


,


,









or,

OR, NHR_2, NR_2, $NR(CH_2)_n$-aryl, $NR(CH_2)_nOR$, COOR, N-pyrrolidone ~~radical~~, OCOR, $NR(CH_2)_nNR_2$, $N[(CH_2)_nNR_2]CO(CH_2)_n$-aryl, $N[(CH_2)_nNHCOOR]CO$-aryl, R^1, $N[CH_2(CH_2)_nOR]_2$, $NR(CH_2)_nNCOOR$, $X(CH_2)_nX(CH_2)_nXR$, $NR(CH_2)_nX(CH_2)_nOH$, $NR(CH_2)_nO(CH_2)_nOH$, $(CH_2)_nCOOR$, $O(CO)NR(CH_2)_nOR$, $O(CO)(CH_2)_nNR_2$, $NR(CH_2)_nNR_2$, $N[(CH_2)_nNR_2]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_nR^1$, $N(R)(CH_2)_nN(R)COOR$, $XCOO(CH_2)_nNR_2$, OSO_2A, OSO_2CF_3, OSO_2Ar, $OCONR_2$, or $OCH_2(CH_2)_nNR_2$

Z ~~denotes~~ is CH_2, X, $CHCONH_2$, $CH(CH_2)_nNRCOOR$, CHNRCOOR, NCO, $CH(CH_2)_nCOOR$, NCOOR, $CH(CH_2)_nOH$, $N(CH_2)_nOH$, $CHNH_2$, $CH(CH_2)_nNR_2$, $CH(CH_2)_nNR_2$, C(OH)R, CHNCOR, $CH(CH_2)_n$-aryl, $CH(CH_2)_n$-heteroaryl, $CH(CH_2)_nR^1$,

$N(CH_2)_nCOOR$, $CH(CH_2)_nX(CH_2)_n$-aryl, $CH(CH_2)_nX(CH_2)_n$-heteroaryl, $N(CH_2)_nCONR_2$, $XCONR(CH_2)_nNR_2$, $N[(CH_2)_nXCOOR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_nX$-aryl, $N[(CH_2)_nXR]SO_2(CH_2)_n$-aryl, $N[(CH_2)_nNRCOOR]CO(CH_2)_n$-aryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-aryl, $N[(CH_2)_nNR_2]CO(CH_2)_nNR$-aryl, $N[(CH_2)_nNR_2]SO_2(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nXR]CO(CH_2)_nX$-heteroaryl, $N[(CH_2)_nXR]SO_2(CH_2)_n$-heteroaryl, $N[(CH_2)_nNRCOOR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_nNR$-heteroaryl, $N[(CH_2)_nNR_2]SO_2(CH_2)_n$-heteroaryl, $O(CH_2)_nNR_2$, $X(CH_2)_nNR_2$, or $NCO(CH_2)_nNR_2$,

R^6 ~~denotes~~ is aryl or heteroaryl, each of which is unsubstituted or mono- or polysubstituted by aryl or heteroaryl, each of which is optionally ~~may be~~ substituted by Hal, NO_2, CN, A, OR, OCOR, COR, NR_2, CF_3, OCF_3, $OCH(CF_3)_2$, ~~or by~~ Hal, NO_2, CN, OR, A, $-(CY_2)_n$-OR, -OCOR, $-(CY_2)_n$-CO_2R, $-(CY_2)_n$-CN, -NCOR, -COR or $-(CY_2)_n$-NR_2,

R^7 ~~denotes~~ is (C=O)-R, (C=O)-NR_2, (C=O)-OR, H or A,

m ~~denotes~~ is 0, 1 or 2,

~~and~~

n ~~denotes~~ is 0, 1, 2, 3, 4, 5, 6 or 7,

~~and~~ or a pharmaceutically usable derivatives~~,~~ solvates~~,~~ tautomers~~,~~ salts ~~and~~ , stereoisomers thereof~~, including~~ or mixtures thereof in ~~all~~ any ratios~~.~~

2. (Currently amended) The compounds according to Claim 1, or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio, in which

R^1 denotes is A, CF_3, OCF_3, SA, SCN, CH_2CN, -OCOA, Hal, SCF_3, t-butyl, $-CH(CH_3)CH_2CH_3$, isopropyl, ethyl or methyl.

3. (Currently amended) The compounds according to Claim 1 or 2 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio in which

R^2 denotes is F or H.

4. (Currently amended) The compounds according to one or more of Claims 1-3 Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio in which

R^3 denotes is F or H.

5. (Currently amended) The compounds according to one or more of Claims 1-4 Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio in which

R^4 preferably denotes is one of the following groups if R^5 denotes H:



or $-X-(CH_2)_2-NR_2$

X and R have the meaning indicated in Claim 1.

6. (Currently amended) The compounds ~~according to one or more of Claims 1-5~~ Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio in which

R^5 ~~denotes~~ is H.

7. (Currently amended) The compounds ~~according to one or more of Claims 1-6~~ Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio in which

R^5, together with R^4, ~~adopts~~ are one of the following ~~meanings~~:



in which

X, R and R^a have the meaning indicated in Claim 1.

8. (Currently amended) The compounds ~~according to~~ Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio ~~one or more of Claims 1-7~~ in which

R^6 ~~denotes~~ is phenyl, 2-, 3- or 4-pyridyl, pyrimidyl, furyl or thienyl, each of which is unsubstituted or mono- or polysubstituted by Hal, CN, NO_2, OH, CF_3, $OCH(CF_3)_2$, $OCOCH_3$ or A.

9. (Currently amended) The compounds ~~according to~~ Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio ~~one or more of Claims 1-8~~ in which

R^6 ~~denotes~~ is one of the following ~~groups~~:



10. (Currently amended) The compounds according to Claim 1 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio ~~one or more of Claims 1-9~~ in which

R^7 ~~denotes~~ is H.

11. (Currently amended) The compounds according to Claim 1, selected from the group consisting of ~~the~~ sub-formulae IA to ID or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio:



IA



IB



IC



ID

in which R, R^1, R^2, R^3, R^4, R^5, R^6, R^7 and X have the meaning indicated in Claim 1.

and

R^8 ~~denotes~~ is H, CH_2OR or CH_2NR_2.

12. (Currently amended) The compounds according to Claim 1 of the sub-formulae A and or B or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio:



A



B

in which R^1, R^2, R^3, R^4, R^5, R^6, R^7 have the meaning indicated in Claim 1, and the ~~race-mate~~ racemate thereof or any other mixtures of ~~the~~ enantiomers thereof.

13. (Currently amended) The compounds according to Claim 1 of ~~the~~ sub-formulae I1 to I45a, or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio:

I1



I1a



I2



I2a



I3



I4



I5



I6


H3C
O
N
OH

I7


CH3
CH3
H3C
O
N
OH
OH

I7a


H3C
CH3
H3C
O
N
OH
OH

I8


CH3
CH3
H3C
O
N
OH

I8a



I9



I9a



I10



I11



I11a



I12



I13



I13a



I14



I14a



I15



I16



I16a



I17



I18



I18a



I19



I19a



I20



I21



I21a



I22



I23



I24



I24a



I25



I26



I27



I27a



I28



I28a



I29



I29a



I30



I30a



I31



I31a



I32



I32a



I33



I33a



I34



I34a



I35



I35a



I36



I36a



I37



I37a



I38



I39



I40



I40a



I41



I41a



I42



I42a



I43



I43a



I44



I45



or

I45a



14. (Currently amended) A method for preparing the compound ~~process for the preparation of compounds of the formula I~~ according to ~~Claims 1-13~~ Claim 1 ~~and~~ or a pharmaceutically usable derivative~~s~~, salt~~s~~, solvate~~s~~, tautomer~~s~~ ~~and~~ , stereoisomer~~s~~ thereof or mixture thereof in any ratio, comprising ~~characterised in~~ that

a compound of ~~the~~ formula II



II

,

in which R^1, R^2 and R^3 have the meanings indicated in Claim 1,

is reacted with a compound of the formula III



III

,

in which
R^6 has the meaning indicated in Claim 1,

and

with a compound of the formula IV, the double-bond isomer thereof (E isomer) or mixtures thereof



IV

,

in which R^4 and R^5 have the meanings indicated in Claim 1,

and, optionally ~~if desired~~, a radical R^7 which denotes H is converted into a radical R^7 which has a meaning other than H,

and/or, optionally ~~if desired~~,
a base or acid of the formula I is converted into one of its salts.

15. (Currently amended) ~~Process~~ The method according to Claim 14, wherein ~~characterised in that~~ the reaction is carried out in ~~the~~ presence of a protonic acid or Lewis acid.

16. (Currently amended) ~~Process~~ The method according to Claim 14 ~~or 15~~, ~~characterised in that~~ wherein the reaction is carried out in ~~the~~ presence of trifluoroacetic acid, hexafluoroisopropanol, bismuth(III) chloride, ytterbium(III) triflate, scandium(III) triflate or cerium(IV) ammonium nitrate.

17. (Currently amended) ~~Medicaments comprising at least one compound of the formula I~~ The compound according to Claim 1 ~~to 13 and/or~~ or a pharmaceutically usable derivative~~s~~, salt~~s~~, solvate~~s~~, tautomer~~s~~, ~~and~~ stereoisomer~~s~~ thereof~~, including~~ or mixtures thereof in ~~all~~ any ratio~~s~~, and optionally an excipient~~s~~ and/or an adjuvant~~s~~, in a pharmaceutical formulation.

18. (Currently amended) A mixture ~~Mixture comprise~~ comprising ~~one or more~~ the compound~~s~~ ~~of the formula I~~ according to Claim 1, or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio, and ~~an amount of one or more~~ a compound~~s~~ of ~~the~~ formula V, or an analogue~~s~~ thereof and/or a metabolite~~s~~ thereof



V

in which

Y' and Z' each, independently of one another, ~~denote~~ are O or N, R^9 and R^{10} each, independently of one another, ~~denote~~ are H, OH, halogen, OC1-10-alkyl, OCF_3, NO_2 or NH_2, ~~n denotes~~ p is an integer between 2 and 6 ~~inclusive~~ inclusively, and R^8 and R^{11} are each, independently of one another, in the meta- or para-position and are selected from the group consisting of:



and,

19. (Currently amended) ~~Use~~ The mixture according to Claim 18, where the compound of the formula V ~~used~~ are pentamidine or salts thereof.

20. (Currently amended) ~~Use of~~ A method comprising administering to a patient the compounds according to Claim 1 ~~to 13 and~~ or a pharmaceutically usable derivatives, salts, solvates, tautomers, ~~and~~ stereoisomers thereof, ~~including~~ or a mixtures thereof in ~~all~~ any ratios, or the mixture according to Claim 18, ~~for the preparation of a medicament~~ for

~~the~~ treatment of diseases which ~~can be~~ are influenced by the inhibition, regulation and/or modulation of the mitotic motor protein Eg5.

21. (Currently amended) ~~Use of~~ A method comprising administering to a patient the compound according to Claim 1 ~~to 13~~ or the mixture according to Claim 18 for ~~the preparation of a medicament for the~~ treatment and prophylaxis of cancer diseases.

22. (Currently amended) ~~Use~~ The method according to Claim 21, where ~~the~~ cancer is ~~diseases are~~ associated with ~~a tumour from the group of tumours of the~~ squamous epithelium, ~~of the~~ bladder, ~~of the~~ stomach, ~~of the~~ kidneys, ~~of~~ head and neck, ~~of the~~ oesophagus, ~~of the~~ cervix, ~~of the~~ thyroid, ~~of the~~ intestine, ~~of the~~ liver, ~~of the~~ brain, ~~of the~~ prostate, ~~of the~~ urogenital tract, ~~of the~~ lymphatic system, ~~of the~~ stomach, ~~of the~~ larynx and/or ~~of the~~ lung.

23. (Currently amended) ~~Use~~ The method according to ~~Claim 22~~ Claim 21, where ~~the tumour~~ cancer originates from ~~the group~~ monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas~~,~~ pancreatic cancer, glioblastomas~~,~~ ~~and~~ breast carcinoma ~~and~~ or colon carcinoma.

24. (Currently amended) ~~Use~~ The method according to Claim 21, where ~~the~~ cancer ~~disease to be treated~~ is ~~a tumour~~ of ~~the~~ blood and immune system.

25. (Currently amended) ~~Use~~ The method according to Claim 24, where ~~the~~ cancer ~~tumour~~ originates from ~~the group~~ acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

26. (Currently amended) ~~Use of compounds of the formula I according to~~ A method comprising administering to a patient the compound of Claim 1 ~~to~~

~~13~~ and/or a ~~physiologically acceptable~~ pharmaceutically usable salts ~~and~~ , solvates~~,~~ tautomer, stereoisomer thereof or mixture thereof in any ratio, for ~~the preparation of a medicament for the~~ treatment of ~~tumours~~ cancer in combination with a therapeutically effective amount of ~~one or more~~ a compounds of the formula V, or an analogues thereof and/or a metabolites thereof.



V

in which

Y' and Z' each, ~~independently~~ of one another, ~~denote~~ are O or N, R^9 and R^{10} each, independently of one another, ~~denote~~ are H, OH, halogen, OC1-10-alkyl, OCF_3, NO_2 or NH_2, ~~n denotes~~ p is an integer between 2 and 6 ~~inclusive~~ inclusively, and R^8 and R^{11} are each, independently of one another, in the meta- or para-position and are selected from the group consisting of:



and,

where

the compounds of the formula I and the compounds of the formula V, or an analogues thereof and/or a metabolites thereof ~~are~~ is administered

simultaneously or within 14 days of one another in amounts which are sufficient to inhibit ~~the~~ growth of a tumour or of other hyperproliferative cells.

27. (Currently amended) ~~Use~~ The method according to Claim 26, where the compound of the formula V used are pentamidine or salts thereof.

28. (Currently amended) ~~Use of compounds of the formula I~~ A method comprising administering to a patient, a therapeutically effective amount of the compound according to Claim 1 ~~to 13~~ and/or ~~physiologically acceptable~~ a pharmaceutically usable salt, ~~and~~ solvate~~s~~, tautomer, stereoisomer thereof or mixture thereof in any ratio for ~~the preparation of a medicament for the~~ treatment of ~~the~~ cancer ~~tumours where a therapeutically effective amount of a compound of the formula I is administered~~ in combination with radiotherapy and a compound selected from the group consisting of 1) an oestrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) ~~further~~ an angiogenesis inhibitor~~s~~.

29. (Currently amended) The compound~~s~~ of the formula I in which Q denotes CH2R^a, and R^a ~~has~~ is one of the following~~s meanings~~: NHR_2, NR_2, $NR(CH_2)_n$aryl, $NR(CH_2)_nOR$, COOR, N-pyrrolidone radical, OCOR, $NR(CH_2)_nNR_2$, $N[(CH_2)_nNR_2]CO(CH_2)_n$aryl, $N[(CH_2)_nNHCOOR]$COaryl, R^1, $N[CH_2(CH_2)_nOR]_2$, $NR(CH_2)_nNCOOR$, $X(CH_2)_nX(CH_2)_nXR$, $NR(CH_2)_nX(CH_2)_nOH$, $NR(CH_2)_nO(CH_2)_nOH$, $(CH_2)_n$COOR, $O(CO)NR(CH_2)_nOR$, $O(CO)(CH_2)_nNR_2$, $NR(CH_2)_nNR_2$, $N[(CH_2)_nNR_2]CO(CH_2)_n$aryl, $N[(CH_2)_nXR]CO(CH_2)_n$aryl,

$N[(CH_2)_nXR]CO(CH_2)_n$heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_nR^1$, $N(R)(CH_2)_nN(R)COOR$, $XCOO(CH_2)_nNR_2$, OSO_2A, OSO_2CF_3, OSO_2Ar, $OCONR_2$ or $OCH_2(CH_2)_nNR$.

30. (New) The compound of Claim 1 of formula IA4 or a pharmaceutically usable derivative, solvate, tautomer, salts, stereoisomer thereof or mixture thereof in any ratio



IA4

in which

R^1 is A, CF_3, OCF_3, SA, SCN, CH_2CN, -OCOA, Hal, SCF_3, t-butyl, $-CH(CH_3)CH_2CH_3$, isopropyl, ethyl or methyl,

R^2 is F or H,

R^3 is H.

R^a is 1-piperazinyl, N-morpholinyl, NHR or NR_2,

R is H or A, in case of geminal radicals R is $-(CH_2)_5-$, $-(CH_2)_4-$, $-(CH_2)_2-X-(CH_2)_2$ or $-(CH_2)_2-Z-(CH_2)_n$,

A is alkyl or cycloalkyl, in which one or more H atoms are optionally replaced by Hal,

Hal is F or Cl,

X is O, S or NR,

Z is CH_2, X, $CHCONH_2$, $CH(CH_2)_nNRCOOR$, CHNRCOOR, NCO, $CH(CH_2)_nCOOR$, NCOOR, $CH(CH_2)_nOH$, $N(CH_2)_nOH$, $CHNH_2$, $CH(CH_2)_nNR_2$, $CH(CH_2)_nNR_2$, C(OH)R, CHNCOR, $CH(CH_2)_n$-aryl, $CH(CH_2)_n$-heteroaryl, $CH(CH_2)_nR^1$, $N(CH_2)_nCOOR$, $CH(CH_2)_nX(CH_2)_n$-aryl, $CH(CH_2)_nX(CH_2)_n$-heteroaryl, $N(CH_2)_nCONR_2$, $XCONR(CH_2)_nNR_2$, $N[(CH_2)_nXCOOR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_nX$-aryl, $N[(CH_2)_nXR]SO_2(CH_2)_n$-aryl, $N[(CH_2)_nNRCOOR]CO(CH_2)_n$-aryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-aryl, $N[(CH_2)_nNR_2]CO(CH_2)_nNR$-aryl, $N[(CH_2)_nNR_2]SO_2(CH_2)_n$-aryl, $N[(CH_2)_nXR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nXR]CO(CH_2)_nX$-heteroaryl, $N[(CH_2)_nXR]SO_2(CH_2)_n$-heteroaryl, $N[(CH_2)_nNRCOOR]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_n$-heteroaryl, $N[(CH_2)_nNR_2]CO(CH_2)_nNR$-heteroaryl, $N[(CH_2)_nNR_2]SO_2(CH_2)_n$-heteroaryl, $O(CH_2)_nNR_2$, $X(CH_2)_nNR_2$, or $NCO(CH_2)_nNR_2$,

R^6 is phenyl, 2-, 3- or 4-pyridyl, pyrimidyl, furyl or thienyl, each of which is unsubstituted or mono- or polysubstituted by Hal, NO_2, CN, OH, CF_3, $OCH(CF_3)_2$, $OCOCH_3$ or A,

R^7 is H or A

n is 0,1,2,3,4,5,6 or 7

or a pharmaceutically useable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture therefore in any ratio.

31. (New) The compound of claim 30 of the following formula or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or a mixture thereof in any ratio:



32. (New) The compound according to Claim 30, or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio, in which alkyl is methyl.

33. (New) The compound according to Claim 30 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio in which

R^7 is H.

34. (New) The compound according to Claim 30 or a pharmaceutically usable derivative, salt, solvate, tautomer, stereoisomer thereof or mixture thereof in any ratio, or optionally an excipient and/or an adjuvant, in a pharmaceutical composition.

35. (New) A mixture comprising the compound according to Claim 30 or a pharmaceutically usable derivative, solvate, tautomer, salt, stereoisomer thereof or mixture thereof in any ratio and a compound of formula V, or an analogue thereof or metabolite thereof



V

in which

Y' and Z' each, independently of one another, are O or N, R^9 and R^{10} each, independently of one another, are H, OH, halogen, OC1-10-alkyl, OCF_3, NO_2 or NH_2, p is an integer between 2 and 6 inclusively, and R^8 and R^{11} are each, independently of one another, in the meta- or para-position and are selected from the group consisting of:



and,

36. (New) The mixture according to Claim 35, wherein the compound of formula V is pentamidine or a salt thereof.

37. (New) A method comprising, administering to a patient the compound according to Claim 30 or a pharmaceutically usable derivative, salt, solvate, tautomer, stereoisomer thereof or mixture thereof in any ratio, for

treatment of disease which can be influenced by the inhibition, regulation and/or modulation of mitotic motor protein Eg5.

38. (New) A method comprising administering to a patient the compound according to Claim 30, or a pharmaceutically usable derivative, salt, solvate, tautomer, stereoisomer thereof or mixture thereof in any ratio for treatment and prophylaxis of cancer.

39. (New) The method according to Claim 38, where the cancer is associated with squamous epithelium, bladder, stomach, kidneys, head and neck, oesophagus, cervix, thyroid, intestine, liver, brain, prostate, urogenital tract, lymphatic system, stomach, larynx and/or lung.

40. (New) The method according to Claim 39, where the cancer originates from monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma.

41. (New) The method according to Claim 38, where the cancer to be treated is of blood and immune system.

42. (New) The method according to Claim 41, where the cancer originates from acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

43. (New) The method comprising administering to a patient a therapeutically effective amount of the compound according to Claim 30 or a pharmaceutically usable derivative, salt, solvate, tautomer, stereoisomer thereof or mixture thereof in any ratio, for treatment of cancer in

combination with a therapeutically effective amount of a compound of the formula V, or an analogue thereof and/or a metabolite thereof.



V

in which

Y' and Z' each, independently of one another, are O or N, R^9 and R^{10} each, independently of one another, are H, OH, halogen, OC1-10-alkyl, OCF_3, NO_2 or NH_2, p is an integer between 2 and 6 inclusively, and R^8 and R^{11} are each, independently of one another, in the meta- or para-position and are selected from the group consisting of:



where

the compound of the formula V and the compound of the formula V, or analogue thereof and/or metabolites thereof are administered simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of a tumour or of other hyperproliferative cells.

44. (New) The method according to Claim 43, wherein the compound of the formula V used is pentamidine or a salt thereof.

45. (New) The method comprising administering to a patient the compound according to Claim 30 or a pharmaceutically usable salt, solvate, tautomer, stereoisomer thereof or mixture thereof in any ratio, for treatment of tumours where a therapeutically effective amount of the compound according to Claim 30 is administered in combination with radiotherapy or a compound selected from the group consisting of 1) an oestrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) an angiogenesis inhibitors.